Home > Insider Trading > Filing (0000950170-24-026635)

Filing Details

Accession Number:: 0000950170-24-026635
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-03-05 20:10:42
Reporting Period:: 2024-03-01

Accepted Time:: 2024-03-05 20:10:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1515673	Ultragenyx Pharmaceutical Inc.	RARE	Pharmaceutical Preparations (2834)	272546083

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1653052	Eric Crombez	C/O Ultragenyx Pharmaceutical Inc. 60 Leveroni Court Novato CA 94949	Evp And Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-03-01	19,400	$0.00	49,912	No	4	A	Direct
Common Stock	Disposition	2024-03-01	1,238	$53.76	48,927	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2024-03-01	34,200	$0.00	34,200	$53.69
Common Stock	Stock Option (Right to Buy)	Acquisiton	2024-03-01	2,351	$0.00	2,351	$67.37

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
34,200		2034-03-01	No	4	A	Direct
2,351		2027-03-01	No	4	A	Direct

Footnotes

Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
Includes 253 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on October 31, 2023.
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On March 1, 2024, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 1,568 shares on that date.